Special Issue "Marine Organohalides"
A special issue of Marine Drugs (ISSN 1660-3397).
Deadline for manuscript submissions: closed (31 August 2016)
Dr. Miguel O. Mitchell
American Institutes for Research, 1000 Thomas Jefferson St NW, Washington, DC 20007, USA
Website | E-Mail
Interests: antibacterial agents; cation-pi and sigma hole-based protein–ligand complex investigations; the interface of chemistry and art; improving low-income accessibility of hands-on chemical instrumentation-based experiments in analytical chemistry and biochemistry
This Special Issue will encompass research pertaining to halogenated marine natural products, their biosynthesis, total synthesis, biological and pharmacological profiles, and halogen bonding to receptors. Articles submitted may be full research papers or reviews covering the past five years (2010–2015). Full research papers claiming to have ascertained molecular structures of natural products or intermediates and final products in the total synthesis of natural products must at a minimum provide IR spectra, proton and carbon NMR spectra, and HRMS as supporting data; HMBC and NOESY specta may be required for compounds of sufficient stereochemical complexity. Syntheses must also contain as supplement detailed, experimental procedures, including isolated yields.
Prof. Dr. Miguel O. Mitchell
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- natural product
- halogen bonding
- receptor binding
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Polybrominated diphenyl ethers (PBDE) revisited: Evidence of the sequestration of PBDE in nudibranch
Authors: Ariyanti S. Dewi 1, Holly E. Urquhart 2, Karen L. Cheney 2, Mary J. Garson 1
Affiliations: 1 School of Chemistry and Molecula Biosciences, University of Queensland, Australia; 2 School of Biological Sciences, University of Queensland, Australia
Abstract: Investigation of the chemistry of the Chromodorid nudibranch, Miamira magnifica is described for the first time. A series of polybrominated diphenyl ethers has been isolated from the extracts of M. magnifica collected in North Stradbroke Island, Australia. A new compound, namely 1-hydroxy-3,4,2’,4’-tetrabromodiphenyl ether, was isolated from the mantle and digestive tissues of the nudibranch. There is an evidence that M. magnifica selectively incorporate tetrabromo- and pentabromo diphenyl ethers in the mantle—but not hexabromo diphenylether—from the sponge diet. The extract of M. miamira was tested in a brine shrimp lethality assay and exhibited a strong activity with an LD50 of 0.05 mg/mL.